title: CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor.
abstract: CEA-related cell adhesion molecule 1 (CEACAM1) exhibits angiogenic properties in in vitro and in vivo angiogenesis assays. CEACAM1 purified from granulocytes and endothelial cell media as well as recombinant CEACAM1 expressed in HEK293 cells stimulate proliferation, chemotaxis, and capillary-like tube formation of human microvascular endothelial cells. They increase vascularization of chick chorioallantoic membrane and potentiate the effects of vascular endothelial growth factor (VEGF)165. VEGF165 increases CEACAM1 expression both on the mRNA and the protein level. VEGF165-induced endothelial tube formation is blocked by a monoclonal CEACAM1 antibody. These data suggest that CEACAM1 is a major effector of VEGF in the early microvessel formation. Since CEACAM1 is expressed in tumor microvessels but not in large blood vessels, CEACAM1 may be a target for the inhibition of tumor angiogenesis.
authors.affiliation: Department of Anatomy, University Hospital Eppendorf, Hamburg, Germany. erguen@uke.uni-hamburg.de
authors.forename: S
authors.initials: S
authors.lastname: Ergün
authors.forename: N
authors.initials: N
authors.lastname: Kilik
authors.forename: G
authors.initials: G
authors.lastname: Ziegeler
authors.forename: A
authors.initials: A
authors.lastname: Hansen
authors.forename: P
authors.initials: P
authors.lastname: Nollau
authors.forename: J
authors.initials: J
authors.lastname: Götze
authors.forename: J H
authors.initials: JH
authors.lastname: Wurmbach
authors.forename: A
authors.initials: A
authors.lastname: Horst
authors.forename: J
authors.initials: J
authors.lastname: Weil
authors.forename: M
authors.initials: M
authors.lastname: Fernando
authors.forename: C
authors.initials: C
authors.lastname: Wagener
mesh_terms: D000251:Adenosine Triphosphatases / Q000235:genetics / Q000302:isolation & purification / Q000494:pharmacology*; D000482:Allantois / Q000187:drug effects; D000818:Animals; D015703:Antigens, CD; D001681:Biological Assay; D001808:Blood Vessels / Q000737:chemistry; D002272:Carcinoembryonic Antigen; D015815:Cell Adhesion Molecules / Q000235:genetics / Q000302:isolation & purification / Q000494:pharmacology*; D002630:Chemotactic Factors / Q000494:pharmacology*; D002642:Chick Embryo; D002823:Chorion / Q000187:drug effects; D004357:Drug Synergism; D016228:Endothelial Growth Factors / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000737:chemistry / Q000187:drug effects*; D006098:Granulocytes / Q000737:chemistry; D006801:Humans; D008222:Lymphokines / Q000494:pharmacology*; D008833:Microcirculation / Q000737:chemistry; D008954:Models, Biological; D009024:Morphogenesis; D009389:Neovascularization, Pathologic; D018919:Neovascularization, Physiologic; D011994:Recombinant Proteins / Q000494:pharmacology; D014018:Tissue Distribution; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D015703:Antigens, CD; C069847:CD66 antigens; D002272:Carcinoembryonic Antigen; D015815:Cell Adhesion Molecules; D002630:Chemotactic Factors; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000251:Adenosine Triphosphatases